Product/Composition:- | Hyperimmune Globulins Intravenous (IV) or Subcutaneous (SC) |
---|---|
Strength:- | 100 mg/mL or 50 mg/mL |
Form:- | Intravenous (IV) or Subcutaneous (SC) Solution |
Reference Brands:- | Tetanus IG (TIG), Varicella Zoster IG, Cytogam,RhoGAM,Hepatitis B Immune Globulin (HBIG)(US) |
MOQ | As per the manufacturer batch size |
Get Quote Send Enquiry on WhatsApp |
Hyperimmune globulins IV provide passive immunity by supplying concentrated, pathogen-specific antibodies. They neutralize viruses or toxins, prevent infections, and support immune defense in exposed or immunocompromised individuals. Benefits include rapid protection, reduced disease severity, and enhanced immune response during post-exposure prophylaxis or treatment of infectious diseases.
Hyperimmune globulins (IV), such as Cytogam or HBIG, are approved in the US by the FDA and in the EU via EMA for passive immunization against specific diseases like CMV, rabies, and hepatitis B. Regulatory approval requires a comprehensive dossier including clinical efficacy, safety data, manufacturing standards, and pharmacovigilance plans. In the US, the FDA reviews detailed submissions for safety and efficacy, while the EMA ensures compliance with regional quality standards. For guidance on dossier preparation, regulatory pathways, and market access strategies, visit PharmaTradz. Ensuring compliance is essential for timely approval and safe worldwide use, supporting effective disease prevention.